

Our Ref: 53526

4 December 2018

southseftonccq.foi@nhs.net

NHS South Sefton CCG

Merton House
Stanley Road
Bootle
Merseyside
L20 3DL

Tel: 0151 317 8456

Email: southsefton.ccg@nhs.net

Re: Freedom of Information Request

Please find below the response to your recent Freedom of Information request regarding Local Enhanced Service for Prolia within NHS South Sefton CCG.

Request/Response:

1. Does your CCG have a 'Local Enhanced Service' (LES) or 'Near Patient Testing' scheme in place with primary care providers for the monitoring or prescribing of Prolia (denosumab) for the treatment of osteoporosis in postmenopausal women or men at increased risk of fractures?

NHS South Sefton CCG have schedules within the CCG Local Quality Contract to support the on-going prescribing, monitoring and administration of denosumab once initiated and stabilised by secondary care.

2. If answer is 'yes' to question 1, please could you provide the pricing arrangement (including cost and time schedule) for Prolia prescribing and Prolia monitoring and any further details of the scheme, for example if Prolia is anticipated to remain within the scheme for the forthcoming year.

Scheme is planned to be continued. The pricing is under review.

3. Does your CCG have a 'Local Enhanced Service' (LES) or 'Near Patient Testing' scheme in place with primary care providers for the monitoring or prescribing of any other osteoporosis therapies. Please could you provide the pricing arrangement (including cost and time schedule) for the prescribing and monitoring of the therapy and any further details of the scheme.

The schedule relating to prescribing includes all drugs which are amber recommended, initiated or retained as per Pan Mersey area prescribing committee.



Chair: Dr Andrew Mimnagh Chief Officer: Fiona Taylor